Mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL): Updated efficacy and safety from the Phase 3 SUNMO study including in second-line (2L) versus third-line plus (3L+) patient subgroups (JADPRO 2026) - Oct 16, 2026 - Abstract #JL1414EH; Pres time: Oct 17, 2026; 11:00 AM - 12:00 PM; Location: Exhibit Hall C; No abstract available
Clinical • P3 data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma
|
|
Wonseog Kim, MD1; Jason Westin, MD, MS2; Dai Maruyama, MD, PhD3; Huilai Zhang, PhD4; Hideki Goto, PhD5; Huangming Hong, MD6; Mark Fesler, MD7; Boone Goodgame, MD8; Zhiming Li, MD9; Eduardo M. Rego, MD10; Adam J. Olszewski, MD11; Nikesh Shah, MD12 Bei Hu, MD13; Shen Yin, PhD14; Hao Wu, PhD14; Martin Janousek, PharmD15; Song Pham, MSc16; Connie Lee Batlevi, MD, PhD14; Michael C. Wei, MD, PhD14; L. Elizabeth Budde, MD17
|